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Sixty-three male 5-week-old Syrian hamsters received the carcinogen N-nitrosobis(2-oxopropyl)amine 
(BOP) s.c.  in 5 weekly injections (the ﬁrst,  70mg/kg body,  and the remaining,  20mg/kg each).  The 
hamsters that received BOP were given intragastric administration of 0.2ml of medium chain triglyc-
eride (MCT) with or without 0.04µg of 1α-hydroxyvitamin D3 [1α(OH)D3] through a feeding tube for 12 
weeks.  Thus,  3 groups were assigned: Group 1; BOP alone (n＝20),  Group 2; BOP＋MCT (n＝18) 
and Group 3; BOP＋1α(OH)D3 (n＝25).  The mean body weight of Group 3 was lower than those of 
Groups 1 and 2 at the end of the experiment (p＜0.001, Tukey-Kramer HSD test).  At the end of week 
12,  all surviving hamsters were put to sleep.  The incidences of liver tumors were 80ｵ,  72ｵ and 32ｵ 
in Groups 1,  2 and 3,  respectively.  The incidence of tumors in Group 3 was signiﬁcantly lower than in 
Group 1 and Group 2 (p＜0.05,  χ2-test).  All tumors were cholangiocarcinoma.  These results indicated 
that BOP-induced cholangiocarcinogenesis was suppressed by the supplemental administration of 1α
(OH)D3.
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holangiocarcinoma (CCA) is an epithelial cancer 
originating from the bile ducts with features of 
cholangiocyte diﬀerentiation.  Even though CCA is 
rare worldwide,  there has been a marked increase in 
the incidence of and mortality due to intrahepatic 
cholangiocarcinoma in the USA,  the UK,  Japan,  and 
Australia [1,  2].  Since early diagnosis is diﬃcult,  
eﬀective protective measures against CCA are needed.  
Epidemiologic studies suggest that the risk factors for 
CCA are primary sclerosing cholangitis,  liver ﬂuke 
infection,  congenital ﬁbropolycystic liver disease,  bile 
duct adenomas,  biliary papillomatosis,  hepatolithiasis,  
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chemical carcinogens,  chronic viral hepatitis,  cir-
rhosis,  chronic non-alcoholic liver disease and obesity 
[3].  Recently,  an association among 1α, 25-
dihydroxyvitamin D3 [1α, 25(OH)2D3],  vitamin D 
receptor (VDR),  and cancer was recognized,  as epi-
demiological studies indicated an inverse relationship 
between the level of vitamin D3 and the risk of a vari-
ety of cancers [4].  Moreover,  1α , 25(OH)2D3 has 
been used in chemoprevention and therapeutics for 
human tumors other than CCA [5,  6].  The expres-
sion of VDR was shown to be compatible with an 
overall favorable prognosis for CCA,  and the human 
CCA cell lines with a high expression of VDR 
responded to high concentrations of vitamin D3 with a 
decrease in cell number [7].  Previously an inhibitory 
eﬀect of vitamin D3 on colon carcinogenesis was 
reported in animals [8,  9].  Therefore,  we examined 
the eﬀect of 1α-hydroxyvitamin D3 [1α(OH)D3] in a 
CCA model.
Materials and Methods
　 Sixty-three male 5-week-old Syrian hamsters were 
obtained from Shimizu Laboratory Supplies Co.,  Ltd.  
(Kyoto,  Japan) 2 weeks before the experiment.  The 
hamsters were housed in plastic cages (3/cage) with 
sterilized wooden chips as bedding in an air-condi-
tioned room at 23±2℃ and 55±5ｵ humidity with 
12h alternating light and dark periods.  The hamsters 
were maintained on a commercial pellet diet (CE-2,  
Clea Japan,  Osaka,  Japan) and tap water ad libitum.  
The calorie sources of CE-2 as fat and protein were 
5.1 and 25.4ｵ,  respectively.  The calcium and phos-
phorus contents were 1.10 and 1.05ｵ (wt/wt),  and 
that of vitamin D3 was 57.5µg/kg CE-2.  Body weight 
and appearance were recorded periodically.
　 N-nitrosobis(2-oxopropyl)amine (BOP) was obtained 
from Okayama Pharmaceutical Industries,  Ltd.  
(Okayama,  Japan) and dissolved in physiological saline 
just before injection.  1α(OH)D3 (Chugai Laboratories,  
Tokyo,  Japan) was dissolved in medium chain triglyc-
eride (MCT) (The Nisshin Oillio Group,  Ltd.,  Tokyo,  
Japan) at the concentration of 0.2µg/ml.
　 Animals received the carcinogen BOP s.c.  in 5 
weekly injections (the ﬁrst at 70mg/kg,  and the oth-
ers at 20mg/kg each) [10].  The animals that received 
BOP were given intragastric administration of 0.2ml 
of MCT with or without 0.04µg of 1α(OH)D3 through 
a feeding tube 3 times weekly for 12 weeks.  Thus,  3 
groups were assigned: Group 1; BOP alone (n＝20),  
Group 2; BOP＋MCT (n＝18) and Group 3; BOP
＋1α(OH)D3 (n＝25).  These treatments were done 
without anesthesia.  Hamsters were observed daily and 
weighed once every 4 weeks.  At the end of week 12,  
all surviving hamsters were put to sleep,  and patho-
logical (macroscopic and histological) examinations 
were done exactly as has been previously described in 
detail [11].  When a macroscopic liver tumor was 
diagnosed as cholangiocarcinoma by histological 
examination,  that animal was included among the 
hamsters with liver tumors.  Serum calcium levels 
were measured using the o-cresolphthalein complex-
one (oCPC) method (Clinimate CA,  Sekisui Medical 
Co.  Ltd.,  Tokyo,  Japan) in heart blood taken at 
autopsy.
　 The χ2-test,  Studentʼs t-test and the Tukey-
Kramer HSD test were used for statistical analysis 
where appropriate.
Results
　 During the experiment there were no notable 
changes in the general appearance of the hamsters.  
The mean body weight of Group 3 was lower than 
those of Groups 1 and 2 at the end of the experiment 
(p＜0.001,  Tukey-Kramer HSD test) (Fig.  1).
　 Table 1 summarizes the data on the incidence of 
cancer.  The incidences of liver tumors were 80ｵ,  
72ｵ and 32ｵ in Groups 1,  2 and 3,  respectively.  
The incidence of tumors in Group 3 was signiﬁcantly 
lower than those in Groups 1 and 2 (p＜0.05,  the 
χ2-test).  There were no metastases in these animals.  
Macroscopically,  liver tumors were whitish and single 
or multiple (Fig.  2) in all 3 groups.  All tumors were 
cholangiocarcinoma.  Microscopically,  these have a 
bile duct pattern but do not contain bile.  The duct-like 
structure is lined by cuboidal or columnar cells that 
are accompanied by abundant connective tissue stroma 
(Fig.  3).  The portal tract is enlarged and contains 
clear spaces,  mainly representing proliferated bile 
ducts (Figs.  3,  4).  The serum calcium levels of ham-
sters given 1α(OH)D3 (16.2±1.9mg/dl,  mean±SD,  n
＝22) were signiﬁcantly higher than those of the 
groups not given 1α(OH)D3 (12.0±1.2mg/dl,  n＝22) 
(p＜0.001,  Studentʼs t-test).
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Table 1　 Incidence and numbers of hamsters with liver tumor
Group Treatment No. ofhamster
Body weight (g)
(mean±SD)
Size (mm)
Range (mean)
No. of hamster with
liver tumors (％)
1 BOP 20 100±30.0　 0.5-10 (4.2) 16 (80)　　
2 BOP＋MCT 18 119±15.0　 0.8-16 (4.5) 13 (72)　　
3 BOP＋
1α(OH)D3
In MCT
25 71.4±19.7＊ 0.5- 9 (3.4)  8 (32)＊＊
MCT: medium chain triglyceride
＊Signiﬁcantly diﬀerent from Group 1 and 2,  p＜0.001 by Tukey-Kramer HSD test.
＊＊Signiﬁcantly diﬀerent from Group 1 and 2,  p＜0.05 by χ2-test.
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Fig. 1　 Growth curve of male Syrian hamsters. １cm
Fig. 2　 Macroscopic appearance of liver tumors in a hamster in 
Group 1.  This appearance was the same in Groups 2 and 3.
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Fig. 3　 A,  Histological appearance of tubular adenocarcinoma,  centrilobular area (C) and portal tract (P) in a hamster in Group 1.  This 
appearance was the same in Groups 2 and 3 (H＆E stain); B,  Higher-power view of tubular adenocarcinoma (H＆E stain).  Scale bar: A,  
200µm; B,  100µm.
Discussion
　 In the present study,  we ﬁrst showed that adminis-
tration of 1α(OH)D3 inhibited BOP-induced cholangio-
carcinogenesis in Syrian hamsters.  The administered 
1α(OH)D3 is metabolized in the liver to 1α, 25(OH)2D3,  
which acts hormonally through its speciﬁc VDR in the 
body [12] including cancerous cells [13,  14].  A 
recent study demonstrated that treatment with 
1α, 25(OH)2D3 in CCA cell lines with a high expres-
sion of VDR signiﬁcantly reduced cell proliferation in 
a dose-dependent manner [7].  The present result was 
consistent with this and provided experimental evi-
dence of the chemopreventive action of 1α(OH)D3 or 
1α, 25(OH)2D3 in cholangiocarcinogenesis.
　 We did not use a vitamin D3-deprived diet as a 
control diet,  since the supplementation of vitamin D3 
to the basal diet might be a practical experiment in 
future clinical work.  There is considerable evidence 
that tumor growth is an angiogenesis-dependent event 
[15].  Mantell demonstrated that 1α, 25(OH)2D3 sig-
niﬁcantly inhibited vascular endothelial growth factor 
(VEGF)-induced endothelial cell sprouting and elonga-
tion in vitro in a dose-dependent manner and had a 
small,  but signiﬁcant,  inhibitory eﬀect on VEGF-
induced endothelial cell proliferation through speciﬁc 
stages of the angiogenic process [16].  Recently,  
Kisker isolated vitamin D binding protein-macrophage 
activating factor (DBP-maf) generated from systemi-
cally available DBP by a human pancreatic cancer cell 
line [17].  Also,  Kalkunte indicated that DBP-maf 
inhibited human endothelial cell proliferation by inhib-
iting DNA synthesis,  and that DBP-maf inhibited 
VEGF signaling by decreasing VEGF-mediated phos-
phorylation of VEGF-2 and extracellular signal-regu-
lated kinase (ERK)1/2,  a downstream target of the 
VEGF signaling cascade [18].  Although the relation-
ship between this antiangiogenetic activity of vitamin 
D3 and the eﬀects of DBP-maf was unclear,  the pres-
ent study suggests that the chemopreventive eﬀects of 
1α(OH)D3 in cholangiocarcinogenesis may be exerted 
through the inhibition of angiogenesis by 1α, 25(OH)2D3 
or DBP-maf.  Also,  it was indicated that macrophages 
activated with DBP-maf were highly tumoricidal 
against a variety of malignancies [19],  which might 
have been part of the mechanism of anti-carcinogenic 
action of vitamin D3.
　 With regard to the hypercalcemia observed in our 
study,  it has been suggested that the anti-carcinogenic 
eﬀect of 1α(OH)D3 is mediated by hypercalcemia,  as 
1α, 25(OH)2D3 was found to decrease the number of 
cell lines derived from human colon cancer in vitro 
[20].  Furthermore,  the mean body weight in Group 
3 was lower at the end of the experiment through 
hypercalcemia in this study.  It was reported that the 
clinical manifestation of hypercalcemia induced appe-
tite loss [21].  According to Fair [22],  the restric-
tion of calories by 10 to 40ｵ decreased cell prolif-
eration and increased apoptosis through anti-angiogenic 
processes,  resulting in the potent anticancer eﬀect of 
caloric restriction.  Thus,  the weight loss that 
occurred presumably through elevated extracellular 
Ca2+ may be a feasible factor in the cancer prevention 
observed in this study.
　 Although further investigation is necessary to 
determine the precise mechanism of our results in 
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Fig. 4　 A,  Histological appearance of hepatic lobules and portal tract (P) in a hamster in Group 3 (H＆E stain); B,  High-power view of 
portal tract (P) (H＆E stain).  Scale bar: A,  200µm; B,  100µm.
view of the many physiological actions of vitamin D3 
[23],  our study may lend support to the ﬁnding that 
vitamin D3 plays a preventive role in cholangiocar-
cinogenesis,  as indicated by experimental studies in 
vitro [7].
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